Gouvernance Alaunos Therapeutics, Inc.

TCRT

US98973P3091

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 14/07/2026			Varia. 5j.	Varia. 1 janv.
2,090 ^USD	+0,29%		+2,45%	-35,29%

29/06	Alaunos Therapeutics publie de nouvelles données précliniques sur l'ALN1003 montrant une réduction du poids du foie après ajustement du taux de graisse corporelle dans une étude de 48 jours sur des souris DIO	CI
26/05	Alaunos Therapeutics fait état d'une amélioration métabolique globale avec l'ALN1003 dans des études sur des souris obèses	CI

Comité Exécutif: Alaunos Therapeutics, Inc.

Dirigeant

Fonctions occupéesDepuis

Holger Weis

63 ans

Chief Executive Officer

02/07/2025

Ferdinand Groenewald

41 ans

Director of Finance/CFO

22/02/2025

Composition du Conseil d'Administration: Alaunos Therapeutics, Inc.

Administrateur

ComitésDepuis

Holger Weis

63 ans

Compensation Committee	22/09/2023
Audit Committee Chair	08/09/2021
Governance Committee	08/09/2021
Nominating Committee	08/09/2021

Jaime Vieser

57 ans

Audit Committee	01/01/2026
Governance Committee	01/12/2024
Nominating Committee	01/12/2024
Compensation Committee Chair	01/12/2024
Compensation Committee	01/01/2026

Robert Postma

72 ans

Audit Committee	05/02/2021
Compensation Committee	05/02/2021
Governance Committee Chair	05/02/2021
Nominating Committee Chair	05/02/2021

Michael Jerman

42 ans

Compensation Committee	15/07/2025
Governance Committee	24/05/2023
Nominating Committee	24/05/2023
Audit Committee Chair	15/07/2025

Dernières Nominations: Alaunos Therapeutics, Inc.

24/02	Price Adrian adresse une lettre à Alaunos Therapeutics Inc	CI
22/07/25	Alaunos Therapeutics, Inc. annonce la démission de Melinda Lackey de son poste de secrétaire générale, effective au 15 août 2025	CI
17/07/25	Alaunos Therapeutics, Inc. nomme Michael A. Jerman au poste d'administrateur, à compter du 17 juillet 2025	CI
18/04/25	Alaunos Therapeutics, Inc. annonce la démission de M. Hofmeister en tant que membre du conseil d'administration, avec effet immédiat.	CI
10/06/24	BioSig Technologies nomme Ferdinand Groenewald directeur financier par intérim	MT
22/01/24	Alaunos Therapeutics, Inc. nomme Dale Curtis Hogue, Jr. au poste de directeur général par intérim	CI
02/01/24	Alaunos Therapeutics, Inc. nomme Dale Curtis Hogue au poste d'administrateur	CI

Plus d'Actualités

Anciens Dirigeants et Administrateurs: Alaunos Therapeutics, Inc.

Insider

Fonctions occupées

DepuisJusqu'au

Mary Thistle

Director/Board Member	15/11/2020	18/12/2023
Independent Dir/Board Member	15/11/2020	18/12/2023

James Huang

Director/Board Member	22/07/2020	14/01/2021
Chairman	14/01/2021	22/09/2023

Christopher Bowden

Director/Board Member	08/10/2019	30/03/2023
Independent Dir/Board Member	08/10/2019	30/03/2023

Eleanor de Groot

Chief Operating Officer	01/09/2021	01/05/2022
Corporate Officer/Principal	01/07/2015	01/09/2021

Raffaele Baffa

Chief Tech/Sci/R&D Officer

17/11/2020

01/04/2022

Kevin Lafond

Comptroller/Controller/Auditor	03/06/2013	08/11/2021
Director of Finance/CFO	03/06/2013	-
Treasurer	03/06/2013	08/11/2021

Heidi Hagen

Director/Board Member	13/06/2019	02/11/2021
Chief Executive Officer	25/02/2021	30/08/2021
Independent Dir/Board Member	30/08/2021	02/11/2021

Lynn M. Ferrucci

Chief Administrative Officer	01/01/2012	01/10/2021
Chief Tech/Sci/R&D Officer	01/01/2012	01/10/2021
Human Resources Officer	01/01/2012	01/10/2021

Robert Hadfield

Compliance Officer	01/12/2018	28/05/2021
General Counsel	01/04/2018	28/05/2021
Corporate Secretary	01/04/2018	28/05/2021

J. Buchi

Director/Board Member	21/09/2020	19/05/2021
Independent Dir/Board Member	21/09/2020	19/05/2021

Laurence Cooper

Director/Board Member	16/10/2018	25/02/2021
Chief Executive Officer	05/05/2015	25/02/2021

Satyavrat Shukla

Director of Finance/CFO

22/07/2019

31/12/2020

Scott Tarriff

Director/Board Member	01/09/2015	01/04/2019
Chairman	01/04/2019	16/12/2020
Independent Dir/Board Member	01/09/2015	16/12/2020

Elan Ezickson

Director/Board Member	18/09/2018	04/12/2020
Independent Dir/Board Member	18/09/2018	04/12/2020

Douglas Pagán

Director/Board Member	18/09/2018	18/09/2020
Independent Dir/Board Member	18/09/2018	18/09/2020

David Mauney

Chief Operating Officer	06/11/2017	13/12/2018
Corporate Officer/Principal	28/09/2017	-
President	13/12/2018	26/05/2020
Private Equity Investor	01/12/2018	02/07/2020

James Cannon

Director/Board Member	01/09/2005	13/06/2019
Independent Dir/Board Member	01/09/2005	13/06/2019

Christopher Taylor

Investor Relations Contact	01/03/2019	-
Public Communications Contact	01/03/2019	-

Francois Lebel

Chief Tech/Sci/R&D Officer	01/02/2013	26/10/2018
Corporate Officer/Principal	01/02/2013	-

Randal Kirk

Director/Board Member

06/01/2011

05/10/2018

Murray Brennan

Director/Board Member	01/09/2005	18/09/2018
Independent Dir/Board Member	01/09/2005	18/09/2018

Wyche Fowler

Director/Board Member	01/09/2005	18/09/2018
Independent Dir/Board Member	01/09/2005	18/09/2018

Michael Weiser

Director/Board Member	01/09/2005	12/03/2018
Independent Dir/Board Member	01/09/2005	12/03/2018

Caesar Belbel

Chief Operating Officer	01/06/2015	06/11/2017
General Counsel	06/09/2011	15/02/2018
Corporate Secretary	06/09/2011	15/02/2018

David Connolly

Investor Relations Contact	28/09/2017	-
Public Communications Contact	28/09/2017	-

Amy Trevvett

Public Communications Contact	07/03/2017	-
Corporate Officer/Principal	07/03/2017	-

Tim McInerney

Director/Board Member	01/09/2005	18/06/2015
Independent Dir/Board Member	01/09/2005	18/06/2015

Jonathan Lewis

Director/Board Member	23/06/2011	11/05/2015
Chief Executive Officer	01/09/2005	05/05/2015
Chief Tech/Sci/R&D Officer	01/09/2005	24/07/2012

Amy Mendel

Corporate Officer/Principal

01/01/2011

01/01/2015

Jason Amello

Director of Finance/CFO	08/05/2012	31/05/2013
Treasurer	31/05/2013	31/05/2013

Jun Lin Ho

Corporate Officer/Principal

01/01/2013

01/05/2013

Hagop Youssoufian

Chief Tech/Sci/R&D Officer

18/07/2011

02/04/2013

Richard Bagley

Director/Board Member	23/06/2011	16/07/2012
Chief Operating Officer	01/09/2005	16/07/2012
Director of Finance/CFO	01/09/2005	09/05/2012
President	01/09/2005	16/07/2012
Treasurer	01/09/2005	09/07/2012

Mark Thornton

Corporate Officer/Principal

05/01/2011

16/07/2012

Michael King

Corporate Officer/Principal

05/10/2010

01/06/2011

Janice Stevens

Corporate Officer/Principal

01/01/2008

02/01/2011

J. Kris Piper

Chief Tech/Sci/R&D Officer	08/11/2010	-
Corporate Officer/Principal	09/11/2010	-

George Abercrombie

Director/Board Member

01/04/2010

08/11/2010

Gary Fragin

Director/Board Member

01/09/2005

23/06/2010

Tyler Cook

Chief Administrative Officer	04/01/2011	-
Chief Tech/Sci/R&D Officer	05/12/2011	-
Human Resources Officer	04/01/2011	05/12/2011
Public Communications Contact	03/06/2010	07/12/2011

Brian L. Hamilton

Chief Tech/Sci/R&D Officer	31/03/2009	31/03/2009
Chief Tech/Sci/R&D Officer	09/11/2010	-

Barry Jones

Chief Tech/Sci/R&D Officer	03/03/2008	22/10/2009
Corporate Officer/Principal	22/10/2009	-

Robert P. Gale

Chief Tech/Sci/R&D Officer

01/01/2004

13/01/2007

Robert Newman

Chief Operating Officer	01/01/2004	-
Chief Tech/Sci/R&D Officer	25/07/2012	-
Corporate Officer/Principal	07/12/2011	25/07/2012

Carlo Casulo

Chief Tech/Sci/R&D Officer

01/03/2006

31/05/2006

Barbara Wallner

Chief Tech/Sci/R&D Officer

01/01/2006

Robert Morgan

Chief Tech/Sci/R&D Officer	01/01/2008	-
General Counsel	01/01/2008	-
Corporate Officer/Principal	01/01/2008	07/12/2011

John Barrett

Chief Tech/Sci/R&D Officer

Nicole P. Jones

Public Communications Contact

Kelly Luethje

Public Communications Contact

Suzanne McKenna

Investor Relations Contact	-	-
Public Communications Contact	-	-

Distribution de l'Âge des Dirigeants

Parité Homme Femme

Homme	5
Femme	0

Dont comité exécutif

Homme	2
Femme	0

Dont Administrateurs

Homme	4
Femme	0

Alaunos Therapeutics, Inc. est une société spécialisée dans la thérapie cellulaire, active au stade préclinique dans le domaine de l’obésité et des troubles métaboliques, et au stade clinique dans le domaine de l’oncologie. La société se concentre sur le développement de petites molécules qui devraient s’avérer efficaces contre l’obésité et d’autres troubles métaboliques. Elle se consacre au développement de nouveaux traitements contre l’obésité à base de petites molécules. Ses activités consistent principalement à mener des travaux de recherche et développement et à lever des fonds pour financer ces efforts. La société n’a généré aucun chiffre d’affaires.

Employés

Secteur

Recherche biotechnologique et médicale

Plus d'informations sur la société